To identify novel combination strategies targeting CD47, a macrophage killing‐based evaluation system was developed, encompassing short‐term phagocytosis assays, long‐term assessments of residual tumor cells, and in vivo phagocytosis analyses (Figure 1). This evidence concerns the gene CD47 and neoplasm.